{"generated":"2026-10-19T13:52:51.838Z","today":"2026-10-19","total":862,"findings":[{"check":"soc-cites-dead","severity":"high","id":"pulmonary-embolism-vq","kind":"indication","name":"Pulmonary embolism: ventilation/perfusion imaging","route":"/indications/pulmonary-embolism-vq/","detail":"standard-of-care row \"Suspected acute pulmonary embolism, intermediate or high pre-test probability, especially pregnancy or contraindication to iodinated contrast\" cites Krypton-81m (status historic) without saying so in the text; explain the negative result or drop the reference"},{"check":"status-vs-approvals","severity":"high","id":"i-125-seeds","kind":"drug","name":"Iodine-125 brachytherapy seeds","route":"/drugs/i-125-seeds/","detail":"status \"approved\" but no approvals recorded"},{"check":"duplicate-name","severity":"medium","id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","detail":"same normalised name as f-dosimetry (section)"},{"check":"duplicate-name","severity":"medium","id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/","detail":"same normalised name as dosimetry (term)"},{"check":"duplicate-name","severity":"medium","id":"f-18-fdg-brain","kind":"drug","name":"Fludeoxyglucose F-18 (brain metabolism)","route":"/drugs/f-18-fdg-brain/","detail":"same normalised name as fludeoxyglucose-f18 (drug)"},{"check":"duplicate-name","severity":"medium","id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","detail":"same normalised name as f-18-fdg-brain (drug)"},{"check":"duplicate-name","severity":"medium","id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","detail":"same normalised name as i-123-mibg-cardiac (drug)"},{"check":"duplicate-name","severity":"medium","id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","detail":"same normalised name as i-123-mibg (drug)"},{"check":"duplicate-name","severity":"medium","id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","detail":"same normalised name as lu-177-dotatate-generic (drug)"},{"check":"duplicate-name","severity":"medium","id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","detail":"same normalised name as lutathera (drug)"},{"check":"duplicate-name","severity":"medium","id":"p-32","kind":"isotope","name":"Phosphorus-32","route":"/isotopes/p-32/","detail":"same normalised name as phosphorus-32 (drug)"},{"check":"duplicate-name","severity":"medium","id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","detail":"same normalised name as p-32 (isotope)"},{"check":"duplicate-name","severity":"medium","id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","detail":"same normalised name as prostate-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","detail":"same normalised name as prostate (indication)"},{"check":"duplicate-name","severity":"medium","id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/","detail":"same normalised name as radioembolisation-tare (technology)"},{"check":"duplicate-name","severity":"medium","id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","detail":"same normalised name as f-radioembolisation (section)"},{"check":"duplicate-name","severity":"medium","id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","detail":"same normalised name as radioligand-therapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","detail":"same normalised name as f-radioligand-therapy (section)"},{"check":"duplicate-name","severity":"medium","id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","detail":"same normalised name as f-alpha-therapy (section)"},{"check":"duplicate-name","severity":"medium","id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","detail":"same normalised name as targeted-alpha-therapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","detail":"same normalised name as theranostics-journal (journal)"},{"check":"duplicate-name","severity":"medium","id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","detail":"same normalised name as theranostics (term)"},{"check":"future-year-in-text","severity":"medium","id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","route":"/journals/chinese-journal-of-nuclear-medicine-and-molecular-imaging/","detail":"mentions 2095"},{"check":"future-year-in-text","severity":"medium","id":"dose-calibrator","kind":"term","name":"Dose calibrator","route":"/terms/dose-calibrator/","detail":"mentions 2060"},{"check":"future-year-in-text","severity":"medium","id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","detail":"mentions 2039"},{"check":"future-year-in-text","severity":"medium","id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"patient-release-criteria","kind":"term","name":"Patient release criteria after radioactive treatment","route":"/terms/patient-release-criteria/","detail":"mentions 2075"},{"check":"future-year-in-text","severity":"medium","id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","detail":"mentions 2030"},{"check":"outcome-no-source","severity":"medium","id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","detail":"1 of 3 structured outcomes carry numbers without a source: Area under the ROC curve, overall population"},{"check":"outcome-no-source","severity":"medium","id":"condor","kind":"trial","name":"CONDOR","route":"/trials/condor/","detail":"1 of 2 structured outcomes carry numbers without a source: Change in intended patient management"},{"check":"outcome-no-source","severity":"medium","id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","detail":"1 of 4 structured outcomes carry numbers without a source: PSA response rate (≥50% decline)"},{"check":"outcome-no-source","severity":"medium","id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","detail":"1 of 2 structured outcomes carry numbers without a source: Detection rate"},{"check":"outcome-no-source","severity":"medium","id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","detail":"1 of 3 structured outcomes carry numbers without a source: Change in aetiological diagnosis"},{"check":"outcome-no-source","severity":"medium","id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","detail":"1 of 3 structured outcomes carry numbers without a source: Verified detection rate of distant (M1) lesions"},{"check":"outcome-no-source","severity":"medium","id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/","detail":"3 of 4 structured outcomes carry numbers without a source: PSA50 response; Pathological complete response; Grade 3/4 toxicity and Clavien-Dindo grade 3-5 surgical complications"},{"check":"outcome-no-source","severity":"medium","id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","detail":"1 of 3 structured outcomes carry numbers without a source: Sensitivity for extraprostatic lesions, Cohort B, vs biopsy"},{"check":"outcome-no-source","severity":"medium","id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","detail":"1 of 1 structured outcome carry numbers without a source: Biochemical failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/","detail":"3 of 4 structured outcomes carry numbers without a source: Objective response rate (RECIST-evaluable subset); Overall survival; Grade 3 immune-related adverse events"},{"check":"outcome-no-source","severity":"medium","id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","detail":"1 of 3 structured outcomes carry numbers without a source: Overall detection rate, all evaluable scans"},{"check":"outcome-no-source","severity":"medium","id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","detail":"2 of 4 structured outcomes carry numbers without a source: PSA progression-free survival; Freedom from castration resistance"},{"check":"status-vs-approvals","severity":"medium","id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","detail":"US/EU approvals recorded (US 2007) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"US/EU approvals recorded (US 2012) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","detail":"US/EU approvals recorded (US 2024) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","detail":"US/EU approvals recorded (US 2008, US 2013) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","detail":"US/EU approvals recorded (US 1989) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","detail":"US/EU approvals recorded (US 1976, US 1976) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","detail":"US/EU approvals recorded (US 1990) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","detail":"US/EU approvals recorded (US 1996, US 1999) but status is \"unset\""},{"check":"status-vs-approvals","severity":"medium","id":"tl-201-chloride","kind":"drug","name":"Thallous chloride Tl-201","route":"/drugs/tl-201-chloride/","detail":"US/EU approvals recorded (US 1977, US 1977) but status is \"unset\""},{"check":"text-vs-structured","severity":"medium","id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","detail":"text says enrolled 400 but enrolled is 233"},{"check":"unsourced-numbers","severity":"medium","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"1 number in the text (10 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"2 numbers in the text (7 percent, 40 percent) but no link, Wikipedia page or registry id"},{"check":"approvals-vs-regional","severity":"low","id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","detail":"regional-approvals.ts records EU approved 1995 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","detail":"regional-approvals.ts records EU approved 2009 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","detail":"regional-approvals.ts records EU approved 1990 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","detail":"regional-approvals.ts records EU approved 1998 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approved-only-live-trials","severity":"low","id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","detail":"status \"approved\" but every linked trial is still running (Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: active, A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"status \"approved\" but every linked trial is still running (TheraSphere With Durvalumab and Tremelimumab for HCC: active, A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"status \"approved\" but every linked trial is still running (PSMA PET Combined With MRI for the Detection of PCa: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"status \"approved\" but every linked trial is still running (FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","detail":"status \"standard-of-care\" but every linked trial is still running (Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"future-year-in-text","severity":"low","id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ac-225-fpi-2068","kind":"drug","name":"Actinium-225 FPI-2068","route":"/drugs/ac-225-fpi-2068/","detail":"mentions 2068, 2053, 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","detail":"mentions 2068 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","detail":"mentions 2057 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","detail":"mentions 2027 (looks forward-looking)"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","detail":"\"psa recurrence\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"psa recurrence\" is also Biochemical recurrence of prostate cancer (prostate-bcr, indication); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mcrpc\" is also Metastatic castration-resistant prostate cancer (prostate-mcrpc, indication); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mhspc\" is also Metastatic hormone-sensitive prostate cancer (prostate-mhspc, indication); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","detail":"\"mcrpc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","detail":"\"mhspc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","detail":"\"standardised uptake value\" is also Standardised uptake value (SUV) (suv, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","detail":"\"radioembolisation\" is also TARE / SIRT (radioembolisation with yttrium-90) (tare, term), Radioembolisation (f-radioembolisation, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","detail":"\"standardised uptake value\" is also Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) (quantitative-imaging-biomarkers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","detail":"\"radioembolisation\" is also Radioembolisation (TARE / SIRT, yttrium-90) (radioembolisation-tare, technology), Radioembolisation (f-radioembolisation, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","detail":"\"theranostics\" is also Theranostics (theranostics-journal, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","detail":"\"theranostics\" is also Theranostics (theranostics, term); cross-link them with `related` or merge if they describe one thing"},{"check":"near-duplicate-name","severity":"low","id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","detail":"name overlaps with Non-metastatic castration-resistant prostate cancer (prostate-nmcrpc)"},{"check":"near-duplicate-name","severity":"low","id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","detail":"name overlaps with Small-cell lung cancer (sclc)"},{"check":"orphan","severity":"low","id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"text-says-approved","severity":"low","id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","detail":"text mentions approval but status is \"unset\""},{"check":"text-says-approved","severity":"low","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/","detail":"text mentions approval but status is \"phase-2\""},{"check":"unsourced","severity":"low","id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","detail":"no external link or Wikipedia reference"}],"staleness":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","asOf":"2026-09-04","days":45},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/","asOf":"2026-09-04","days":45},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","asOf":"2026-09-04","days":45},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","asOf":"2026-09-04","days":45},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","asOf":"2026-09-04","days":45},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","asOf":"2026-09-04","days":45},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","asOf":"2026-09-04","days":45},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","asOf":"2026-09-04","days":45},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","asOf":"2026-09-04","days":45},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","asOf":"2026-09-04","days":45},{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","asOf":"2026-09-04","days":45},{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","asOf":"2026-09-04","days":45},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","asOf":"2026-09-04","days":45},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","asOf":"2026-09-04","days":45},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","asOf":"2026-09-04","days":45},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","asOf":"2026-09-04","days":45},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","asOf":"2026-09-04","days":45},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","asOf":"2026-09-04","days":45},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","asOf":"2026-09-04","days":45},{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","asOf":"2026-09-04","days":45},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","asOf":"2026-09-04","days":45},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","asOf":"2026-09-04","days":45},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","asOf":"2026-09-04","days":45},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","asOf":"2026-09-04","days":45},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","asOf":"2026-09-04","days":45},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","asOf":"2026-09-04","days":45},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","asOf":"2026-09-04","days":45},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","asOf":"2026-09-04","days":45},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","asOf":"2026-09-04","days":45},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","asOf":"2026-09-04","days":45},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","asOf":"2026-09-04","days":45},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","asOf":"2026-09-04","days":45},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","asOf":"2026-09-04","days":45},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","asOf":"2026-09-04","days":45},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","asOf":"2026-09-04","days":45},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","asOf":"2026-09-04","days":45},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","asOf":"2026-09-04","days":45},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","asOf":"2026-09-04","days":45},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","asOf":"2026-09-04","days":45},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","asOf":"2026-09-04","days":45},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","asOf":"2026-09-04","days":45},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","asOf":"2026-09-04","days":45},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","asOf":"2026-09-04","days":45},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","asOf":"2026-09-04","days":45},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","asOf":"2026-09-04","days":45},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","asOf":"2026-09-04","days":45},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","asOf":"2026-09-04","days":45},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","asOf":"2026-09-04","days":45},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","asOf":"2026-09-04","days":45},{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","asOf":"2026-09-04","days":45},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","asOf":"2026-09-04","days":45},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","asOf":"2026-09-04","days":45},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","asOf":"2026-09-04","days":45},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","asOf":"2026-09-04","days":45},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","asOf":"2026-09-04","days":45},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","asOf":"2026-09-04","days":45},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","asOf":"2026-09-04","days":45},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","asOf":"2026-09-04","days":45},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","asOf":"2026-09-04","days":45},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","asOf":"2026-09-04","days":45},{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","asOf":"2026-09-04","days":45},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","asOf":"2026-09-04","days":45},{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","asOf":"2026-09-04","days":45},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","asOf":"2026-09-04","days":45},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","asOf":"2026-09-04","days":45},{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","asOf":"2026-09-04","days":45},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","asOf":"2026-09-04","days":45},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","asOf":"2026-09-04","days":45},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","asOf":"2026-09-04","days":45},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","asOf":"2026-09-04","days":45},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","asOf":"2026-09-04","days":45},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","asOf":"2026-09-04","days":45},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","asOf":"2026-09-04","days":45},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","asOf":"2026-09-04","days":45},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","asOf":"2026-09-04","days":45},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","asOf":"2026-09-04","days":45},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","asOf":"2026-09-04","days":45},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","asOf":"2026-09-04","days":45},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","asOf":"2026-09-04","days":45},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","asOf":"2026-09-04","days":45},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","asOf":"2026-09-04","days":45},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","asOf":"2026-09-04","days":45},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","asOf":"2026-09-04","days":45},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","asOf":"2026-09-04","days":45},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","asOf":"2026-09-04","days":45},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","asOf":"2026-09-04","days":45},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","asOf":"2026-09-04","days":45},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","asOf":"2026-09-04","days":45},{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","asOf":"2026-09-04","days":45},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","asOf":"2026-09-04","days":45},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","asOf":"2026-09-04","days":45},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","asOf":"2026-09-04","days":45},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","asOf":"2026-09-04","days":45},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","asOf":"2026-09-04","days":45},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","asOf":"2026-09-04","days":45},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","asOf":"2026-09-04","days":45},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","asOf":"2026-09-04","days":45},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","asOf":"2026-09-04","days":45},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","asOf":"2026-09-04","days":45},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","asOf":"2026-09-04","days":45},{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","asOf":"2026-09-04","days":45},{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","asOf":"2026-09-04","days":45},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","asOf":"2026-09-04","days":45},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","asOf":"2026-09-04","days":45},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","asOf":"2026-09-04","days":45},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","asOf":"2026-09-04","days":45},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","asOf":"2026-09-06","days":43},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","asOf":"2026-09-06","days":43},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","asOf":"2026-09-06","days":43},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","asOf":"2026-09-06","days":43},{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","asOf":"2026-09-06","days":43},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","asOf":"2026-09-06","days":43},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","asOf":"2026-09-06","days":43},{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","asOf":"2026-09-06","days":43},{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","asOf":"2026-09-06","days":43},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","asOf":"2026-09-06","days":43},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","asOf":"2026-09-06","days":43},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","asOf":"2026-09-06","days":43},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","asOf":"2026-09-06","days":43},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","asOf":"2026-09-06","days":43},{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","asOf":"2026-09-06","days":43},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","asOf":"2026-09-06","days":43},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","asOf":"2026-09-06","days":43},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","asOf":"2026-09-06","days":43},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","asOf":"2026-09-06","days":43},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","asOf":"2026-09-06","days":43},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","asOf":"2026-09-06","days":43},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","asOf":"2026-09-06","days":43},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","asOf":"2026-09-06","days":43},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","asOf":"2026-09-06","days":43},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","asOf":"2026-09-06","days":43},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","asOf":"2026-09-06","days":43},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","asOf":"2026-09-07","days":42},{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","asOf":"2026-09-07","days":42},{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/","asOf":"2026-09-07","days":42},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","asOf":"2026-09-07","days":42},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","asOf":"2026-09-07","days":42},{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","asOf":"2026-09-07","days":42},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","asOf":"2026-09-07","days":42},{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","asOf":"2026-09-07","days":42},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","asOf":"2026-09-07","days":42},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","asOf":"2026-09-07","days":42},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","asOf":"2026-09-07","days":42},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","asOf":"2026-09-07","days":42},{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","asOf":"2026-09-07","days":42},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","asOf":"2026-09-07","days":42},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","asOf":"2026-09-07","days":42},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","asOf":"2026-09-07","days":42},{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","asOf":"2026-09-07","days":42},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","asOf":"2026-09-07","days":42},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","asOf":"2026-09-07","days":42},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","asOf":"2026-09-07","days":42},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","asOf":"2026-09-07","days":42},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","asOf":"2026-09-07","days":42},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","asOf":"2026-09-07","days":42},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","asOf":"2026-09-07","days":42},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","asOf":"2026-09-07","days":42},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","asOf":"2026-09-07","days":42},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","asOf":"2026-09-07","days":42},{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","asOf":"2026-09-07","days":42},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","asOf":"2026-09-07","days":42},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","asOf":"2026-09-07","days":42},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","asOf":"2026-09-07","days":42},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","asOf":"2026-09-07","days":42},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","asOf":"2026-09-07","days":42},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","asOf":"2026-09-07","days":42},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","asOf":"2026-09-07","days":42},{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","asOf":"2026-09-07","days":42},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","asOf":"2026-09-07","days":42},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","asOf":"2026-09-07","days":42},{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","asOf":"2026-09-07","days":42},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","asOf":"2026-09-07","days":42},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","asOf":"2026-09-07","days":42},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","asOf":"2026-09-07","days":42},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","asOf":"2026-09-07","days":42},{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","asOf":"2026-09-07","days":42},{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","asOf":"2026-09-07","days":42},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","asOf":"2026-09-07","days":42},{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","asOf":"2026-09-08","days":41},{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","asOf":"2026-09-08","days":41},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","asOf":"2026-09-08","days":41},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","asOf":"2026-09-08","days":41},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","asOf":"2026-09-08","days":41},{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","asOf":"2026-09-08","days":41},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","asOf":"2026-09-08","days":41},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","asOf":"2026-09-08","days":41},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","asOf":"2026-09-08","days":41},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","asOf":"2026-09-08","days":41},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","asOf":"2026-09-08","days":41},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","asOf":"2026-09-08","days":41},{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","asOf":"2026-09-08","days":41},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","asOf":"2026-09-08","days":41},{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","asOf":"2026-09-08","days":41},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","asOf":"2026-09-08","days":41},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","asOf":"2026-09-08","days":41},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","asOf":"2026-09-08","days":41},{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","asOf":"2026-09-08","days":41},{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","asOf":"2026-09-08","days":41},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","asOf":"2026-09-08","days":41},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","asOf":"2026-09-08","days":41},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","asOf":"2026-09-08","days":41},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","asOf":"2026-09-08","days":41},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","asOf":"2026-09-08","days":41},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","asOf":"2026-09-08","days":41},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","asOf":"2026-09-08","days":41},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","asOf":"2026-09-08","days":41},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","asOf":"2026-09-08","days":41},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","asOf":"2026-09-08","days":41},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","asOf":"2026-09-08","days":41},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","asOf":"2026-09-08","days":41},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","asOf":"2026-09-08","days":41},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","asOf":"2026-09-08","days":41},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","asOf":"2026-09-08","days":41},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","asOf":"2026-09-08","days":41},{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","asOf":"2026-09-08","days":41},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","asOf":"2026-09-08","days":41},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","asOf":"2026-09-08","days":41},{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","asOf":"2026-09-08","days":41},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","asOf":"2026-09-08","days":41},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","asOf":"2026-09-08","days":41},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","asOf":"2026-09-08","days":41},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","asOf":"2026-09-08","days":41},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","asOf":"2026-09-08","days":41},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","asOf":"2026-09-08","days":41},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","asOf":"2026-09-08","days":41},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","asOf":"2026-09-08","days":41},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","asOf":"2026-09-08","days":41},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","asOf":"2026-09-08","days":41},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","asOf":"2026-09-08","days":41},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","asOf":"2026-09-08","days":41},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","asOf":"2026-09-08","days":41},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","asOf":"2026-09-08","days":41},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","asOf":"2026-09-08","days":41},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","asOf":"2026-09-08","days":41},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","asOf":"2026-09-08","days":41},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","asOf":"2026-09-08","days":41},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","asOf":"2026-09-08","days":41},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","asOf":"2026-09-08","days":41},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","asOf":"2026-09-08","days":41},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","asOf":"2026-09-08","days":41},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","asOf":"2026-09-08","days":41},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","asOf":"2026-09-08","days":41},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","asOf":"2026-09-08","days":41},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","asOf":"2026-09-09","days":40},{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","asOf":"2026-09-09","days":40},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","asOf":"2026-09-09","days":40},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","asOf":"2026-09-09","days":40},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","asOf":"2026-09-09","days":40},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","asOf":"2026-09-09","days":40},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","asOf":"2026-09-09","days":40},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","asOf":"2026-09-09","days":40},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","asOf":"2026-09-09","days":40},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","asOf":"2026-09-09","days":40},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","asOf":"2026-09-09","days":40},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","asOf":"2026-09-09","days":40},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","asOf":"2026-09-09","days":40},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","asOf":"2026-09-09","days":40},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","asOf":"2026-09-09","days":40},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","asOf":"2026-09-09","days":40},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","asOf":"2026-09-09","days":40},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","asOf":"2026-09-09","days":40},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","asOf":"2026-09-09","days":40},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","asOf":"2026-09-09","days":40},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","asOf":"2026-09-09","days":40},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","asOf":"2026-09-09","days":40},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","asOf":"2026-09-09","days":40},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","asOf":"2026-09-09","days":40},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","asOf":"2026-09-09","days":40},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","asOf":"2026-09-09","days":40},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","asOf":"2026-09-09","days":40},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","asOf":"2026-09-09","days":40},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","asOf":"2026-09-09","days":40},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","asOf":"2026-09-09","days":40},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","asOf":"2026-09-09","days":40},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","asOf":"2026-09-09","days":40},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","asOf":"2026-09-09","days":40},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","asOf":"2026-09-09","days":40},{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","asOf":"2026-09-09","days":40},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","asOf":"2026-09-09","days":40},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","asOf":"2026-09-09","days":40},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","asOf":"2026-09-09","days":40},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","asOf":"2026-09-09","days":40},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","asOf":"2026-09-09","days":40},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","asOf":"2026-09-09","days":40},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","asOf":"2026-09-09","days":40},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","asOf":"2026-09-09","days":40},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","asOf":"2026-09-09","days":40},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","asOf":"2026-09-09","days":40},{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","asOf":"2026-09-09","days":40},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","asOf":"2026-09-09","days":40},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","asOf":"2026-09-09","days":40},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","asOf":"2026-09-09","days":40},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","asOf":"2026-09-09","days":40},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","asOf":"2026-09-09","days":40},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","asOf":"2026-09-09","days":40},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","asOf":"2026-09-09","days":40},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","asOf":"2026-09-09","days":40},{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","asOf":"2026-09-09","days":40},{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","asOf":"2026-09-09","days":40},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","asOf":"2026-09-09","days":40},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","asOf":"2026-09-09","days":40},{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","asOf":"2026-09-09","days":40},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","asOf":"2026-09-09","days":40},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","asOf":"2026-09-09","days":40},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","asOf":"2026-09-09","days":40},{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","asOf":"2026-09-09","days":40},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","asOf":"2026-09-09","days":40},{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","asOf":"2026-09-10","days":39},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","asOf":"2026-09-10","days":39},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","asOf":"2026-09-10","days":39},{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","asOf":"2026-09-10","days":39},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","asOf":"2026-09-10","days":39},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","asOf":"2026-09-10","days":39},{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","asOf":"2026-09-10","days":39},{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","asOf":"2026-09-10","days":39},{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/","asOf":"2026-09-10","days":39},{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/","asOf":"2026-09-10","days":39},{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","asOf":"2026-09-10","days":39},{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","asOf":"2026-09-10","days":39},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","asOf":"2026-09-10","days":39},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","asOf":"2026-09-10","days":39},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","asOf":"2026-09-10","days":39},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","asOf":"2026-09-10","days":39},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","asOf":"2026-09-10","days":39},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","asOf":"2026-09-10","days":39},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","asOf":"2026-09-10","days":39},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","asOf":"2026-09-10","days":39},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","asOf":"2026-09-10","days":39},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","asOf":"2026-09-10","days":39},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","asOf":"2026-09-10","days":39},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","asOf":"2026-09-10","days":39},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","asOf":"2026-09-10","days":39},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","asOf":"2026-09-10","days":39},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","asOf":"2026-09-10","days":39},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","asOf":"2026-09-10","days":39},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","asOf":"2026-09-10","days":39},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","asOf":"2026-09-10","days":39},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","asOf":"2026-09-10","days":39},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","asOf":"2026-09-10","days":39},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","asOf":"2026-09-10","days":39},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","asOf":"2026-09-10","days":39},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","asOf":"2026-09-10","days":39},{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","asOf":"2026-09-10","days":39},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","asOf":"2026-09-10","days":39},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","asOf":"2026-09-10","days":39},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","asOf":"2026-09-10","days":39},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","asOf":"2026-09-10","days":39},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","asOf":"2026-09-10","days":39},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","asOf":"2026-09-10","days":39},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","asOf":"2026-09-10","days":39},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","asOf":"2026-09-10","days":39},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","asOf":"2026-09-10","days":39},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","asOf":"2026-09-10","days":39},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","asOf":"2026-09-10","days":39},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","asOf":"2026-09-10","days":39},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","asOf":"2026-09-10","days":39},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","asOf":"2026-09-10","days":39},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","asOf":"2026-09-10","days":39},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","asOf":"2026-09-10","days":39},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","asOf":"2026-09-10","days":39},{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","asOf":"2026-09-11","days":38},{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","asOf":"2026-09-11","days":38},{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/","asOf":"2026-09-11","days":38},{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","asOf":"2026-09-11","days":38},{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","asOf":"2026-09-11","days":38},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","asOf":"2026-09-11","days":38},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","asOf":"2026-09-11","days":38},{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","asOf":"2026-09-11","days":38},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","asOf":"2026-09-11","days":38},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","asOf":"2026-09-11","days":38},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","asOf":"2026-09-11","days":38},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","asOf":"2026-09-11","days":38},{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","asOf":"2026-09-11","days":38},{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","asOf":"2026-09-11","days":38},{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","asOf":"2026-09-11","days":38},{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","asOf":"2026-09-11","days":38},{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","asOf":"2026-09-11","days":38},{"id":"girentuximab-zr89","kind":"drug","name":"Zirconium-89 girentuximab","route":"/drugs/girentuximab-zr89/","asOf":"2026-09-16","days":33},{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/","asOf":"2026-09-16","days":33},{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/","asOf":"2026-09-16","days":33},{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/","asOf":"2026-09-16","days":33},{"id":"nct03444844","kind":"trial","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","route":"/trials/nct03444844/","asOf":"2026-09-16","days":33},{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","asOf":"2026-09-16","days":33},{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","asOf":"2026-09-16","days":33},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","asOf":"2026-09-16","days":33},{"id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","asOf":"2026-09-16","days":33},{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","asOf":"2026-09-16","days":33},{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","asOf":"2026-09-16","days":33},{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/","asOf":"2026-09-16","days":33},{"id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","asOf":"2026-09-16","days":33},{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/","asOf":"2026-09-16","days":33},{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","asOf":"2026-09-16","days":33},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","asOf":"2026-09-16","days":33},{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/","asOf":"2026-09-16","days":33},{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","asOf":"2026-09-16","days":33},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","asOf":"2026-09-16","days":33},{"id":"nct05219500","kind":"trial","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","route":"/trials/nct05219500/","asOf":"2026-09-16","days":33},{"id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","asOf":"2026-09-16","days":33},{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/","asOf":"2026-09-16","days":33},{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/","asOf":"2026-09-16","days":33},{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/","asOf":"2026-09-16","days":33},{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","asOf":"2026-09-16","days":33},{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","asOf":"2026-09-16","days":33},{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/","asOf":"2026-09-16","days":33},{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/","asOf":"2026-09-16","days":33},{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","asOf":"2026-09-16","days":33},{"id":"nct05849298","kind":"trial","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","route":"/trials/nct05849298/","asOf":"2026-09-16","days":33},{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/","asOf":"2026-09-16","days":33},{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/","asOf":"2026-09-16","days":33},{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","asOf":"2026-09-16","days":33},{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/","asOf":"2026-09-16","days":33},{"id":"nct06040099","kind":"trial","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","route":"/trials/nct06040099/","asOf":"2026-09-16","days":33},{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","route":"/trials/nct06084806/","asOf":"2026-09-16","days":33},{"id":"nct06107374","kind":"trial","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","route":"/trials/nct06107374/","asOf":"2026-09-16","days":33},{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/","asOf":"2026-09-16","days":33},{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","asOf":"2026-09-16","days":33},{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","asOf":"2026-09-16","days":33},{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/","asOf":"2026-09-16","days":33},{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","asOf":"2026-09-16","days":33},{"id":"nct06298916","kind":"trial","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","route":"/trials/nct06298916/","asOf":"2026-09-16","days":33},{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","asOf":"2026-09-16","days":33},{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/","asOf":"2026-09-16","days":33},{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/","asOf":"2026-09-16","days":33},{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","asOf":"2026-09-16","days":33},{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","asOf":"2026-09-16","days":33},{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","asOf":"2026-09-16","days":33},{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","asOf":"2026-09-16","days":33},{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","asOf":"2026-09-16","days":33},{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","asOf":"2026-09-16","days":33},{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","asOf":"2026-09-16","days":33},{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","asOf":"2026-09-16","days":33},{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","asOf":"2026-09-16","days":33},{"id":"nct06750419","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","route":"/trials/nct06750419/","asOf":"2026-09-16","days":33},{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/","asOf":"2026-09-16","days":33},{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","asOf":"2026-09-16","days":33},{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/","asOf":"2026-09-16","days":33},{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","asOf":"2026-09-16","days":33},{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","asOf":"2026-09-16","days":33},{"id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","asOf":"2026-09-16","days":33},{"id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","asOf":"2026-09-16","days":33},{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","asOf":"2026-09-16","days":33},{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","asOf":"2026-09-16","days":33},{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","asOf":"2026-09-16","days":33},{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","asOf":"2026-09-16","days":33},{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","asOf":"2026-09-16","days":33},{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","asOf":"2026-09-16","days":33},{"id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","asOf":"2026-09-16","days":33},{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","asOf":"2026-09-16","days":33},{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","asOf":"2026-09-16","days":33},{"id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","asOf":"2026-09-16","days":33},{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","asOf":"2026-09-16","days":33},{"id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","asOf":"2026-09-16","days":33},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","asOf":"2026-09-16","days":33},{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","asOf":"2026-09-16","days":33},{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","asOf":"2026-09-16","days":33},{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","asOf":"2026-09-16","days":33},{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","asOf":"2026-09-16","days":33},{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","asOf":"2026-09-16","days":33},{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","asOf":"2026-09-16","days":33},{"id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","asOf":"2026-09-16","days":33},{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/","asOf":"2026-09-16","days":33},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","asOf":"2026-09-16","days":33},{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/","asOf":"2026-09-17","days":32},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","asOf":"2026-09-17","days":32},{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","asOf":"2026-09-17","days":32},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","asOf":"2026-09-17","days":32},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","asOf":"2026-09-17","days":32},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","asOf":"2026-09-17","days":32},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","asOf":"2026-09-17","days":32},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","asOf":"2026-09-17","days":32},{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","asOf":"2026-09-17","days":32},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","asOf":"2026-09-17","days":32},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","asOf":"2026-09-17","days":32},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","asOf":"2026-09-17","days":32},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","asOf":"2026-09-17","days":32},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","asOf":"2026-09-17","days":32},{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","asOf":"2026-09-17","days":32},{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","asOf":"2026-09-17","days":32},{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/","asOf":"2026-09-17","days":32},{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","asOf":"2026-09-17","days":32},{"id":"in-vivo-dosimetry","kind":"technology","name":"In vivo dosimetry and patient-specific quality assurance","route":"/technologies/in-vivo-dosimetry/","asOf":"2026-09-17","days":32},{"id":"ldr-seed-brachytherapy","kind":"technology","name":"Low-dose-rate seed brachytherapy","route":"/technologies/ldr-seed-brachytherapy/","asOf":"2026-09-17","days":32},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","asOf":"2026-09-17","days":32},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","asOf":"2026-09-17","days":32},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","asOf":"2026-09-17","days":32},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","asOf":"2026-09-17","days":32},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","asOf":"2026-09-17","days":32},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","asOf":"2026-09-17","days":32},{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","asOf":"2026-09-17","days":32},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","asOf":"2026-09-17","days":32},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","asOf":"2026-09-17","days":32},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","asOf":"2026-09-17","days":32},{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","asOf":"2026-09-17","days":32},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","asOf":"2026-09-17","days":32},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","asOf":"2026-09-17","days":32},{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","asOf":"2026-09-17","days":32},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","asOf":"2026-09-17","days":32},{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","asOf":"2026-09-17","days":32},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","asOf":"2026-09-17","days":32},{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","asOf":"2026-09-17","days":32},{"id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","asOf":"2026-09-17","days":32},{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","asOf":"2026-09-17","days":32},{"id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","asOf":"2026-09-17","days":32},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","asOf":"2026-09-17","days":32},{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","asOf":"2026-09-17","days":32},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","asOf":"2026-09-17","days":32},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","asOf":"2026-09-17","days":32},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","asOf":"2026-09-17","days":32},{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","asOf":"2026-09-17","days":32},{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","asOf":"2026-09-17","days":32},{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","asOf":"2026-09-17","days":32},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","asOf":"2026-09-17","days":32},{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","asOf":"2026-09-17","days":32},{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","asOf":"2026-09-17","days":32},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","asOf":"2026-09-18","days":31},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","asOf":"2026-09-18","days":31},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","asOf":"2026-09-18","days":31},{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","asOf":"2026-09-18","days":31},{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","asOf":"2026-09-18","days":31},{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","asOf":"2026-09-22","days":27},{"id":"coronary-artery-disease","kind":"indication","name":"Coronary artery disease","route":"/indications/coronary-artery-disease/","asOf":"2026-09-22","days":27},{"id":"cardiac-amyloidosis-attr","kind":"indication","name":"Cardiac amyloidosis (transthyretin, ATTR-CM)","route":"/indications/cardiac-amyloidosis-attr/","asOf":"2026-09-22","days":27},{"id":"cardiac-sarcoidosis","kind":"indication","name":"Cardiac sarcoidosis","route":"/indications/cardiac-sarcoidosis/","asOf":"2026-09-22","days":27},{"id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","asOf":"2026-09-22","days":27},{"id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","asOf":"2026-09-22","days":27},{"id":"tl-201-chloride","kind":"drug","name":"Thallous chloride Tl-201","route":"/drugs/tl-201-chloride/","asOf":"2026-09-22","days":27},{"id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","asOf":"2026-09-22","days":27},{"id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","asOf":"2026-09-22","days":27},{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","asOf":"2026-09-22","days":27},{"id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","asOf":"2026-09-22","days":27},{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","asOf":"2026-09-22","days":27},{"id":"asnc","kind":"institution","name":"American Society of Nuclear Cardiology","route":"/institutions/asnc/","asOf":"2026-09-22","days":27},{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","asOf":"2026-09-22","days":27},{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/","asOf":"2026-09-22","days":27},{"id":"csnm","kind":"institution","name":"Chinese Society of Nuclear Medicine","route":"/institutions/csnm/","asOf":"2026-09-22","days":27},{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/","asOf":"2026-09-22","days":27},{"id":"brit","kind":"institution","name":"Board of Radiation and Isotope Technology","route":"/institutions/brit/","asOf":"2026-09-22","days":27},{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","route":"/companies/nihon-medi-physics/","asOf":"2026-09-22","days":27},{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","asOf":"2026-09-22","days":27},{"id":"china-isotope-radiation","kind":"company","name":"China Isotope & Radiation Corporation","route":"/companies/china-isotope-radiation/","asOf":"2026-09-22","days":27},{"id":"hta-atom-hi-tech","kind":"company","name":"HTA (Atom Hi-Tech)","route":"/companies/hta-atom-hi-tech/","asOf":"2026-09-22","days":27},{"id":"cellbion","kind":"company","name":"CellBion","route":"/companies/cellbion/","asOf":"2026-09-22","days":27},{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","asOf":"2026-09-22","days":27},{"id":"annals-of-nuclear-medicine","kind":"journal","name":"Annals of Nuclear Medicine","route":"/journals/annals-of-nuclear-medicine/","asOf":"2026-09-22","days":27},{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/","asOf":"2026-09-22","days":27},{"id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","route":"/journals/chinese-journal-of-nuclear-medicine-and-molecular-imaging/","asOf":"2026-09-22","days":27},{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","asOf":"2026-09-22","days":27},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","asOf":"2026-09-22","days":27},{"id":"f-18-naf","kind":"drug","name":"Sodium fluoride F-18","route":"/drugs/f-18-naf/","asOf":"2026-09-22","days":27},{"id":"ga-68-fapi-46","kind":"drug","name":"Gallium-68 FAPI-46","route":"/drugs/ga-68-fapi-46/","asOf":"2026-09-22","days":27},{"id":"ga-68-pentixafor","kind":"drug","name":"Gallium-68 pentixafor","route":"/drugs/ga-68-pentixafor/","asOf":"2026-09-22","days":27},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","asOf":"2026-09-22","days":27},{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/","asOf":"2026-09-22","days":27},{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","route":"/drugs/in-111-pentetreotide/","asOf":"2026-09-22","days":27},{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","asOf":"2026-09-22","days":27},{"id":"f-18-fdopa","kind":"drug","name":"Fluorodopa F-18","route":"/drugs/f-18-fdopa/","asOf":"2026-09-22","days":27},{"id":"tc-99m-mdp","kind":"drug","name":"Technetium Tc-99m medronate (MDP)","route":"/drugs/tc-99m-mdp/","asOf":"2026-09-22","days":27},{"id":"cu-64-sar-bispsma","kind":"drug","name":"Copper-64 SAR-bisPSMA","route":"/drugs/cu-64-sar-bispsma/","asOf":"2026-09-22","days":27},{"id":"tc-99m-psma-imaging","kind":"drug","name":"Technetium Tc-99m PSMA agents (PSMA-I&S)","route":"/drugs/tc-99m-psma-imaging/","asOf":"2026-09-22","days":27},{"id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/","asOf":"2026-09-22","days":27},{"id":"ga-67-citrate","kind":"drug","name":"Gallium citrate Ga-67","route":"/drugs/ga-67-citrate/","asOf":"2026-09-22","days":27},{"id":"alzheimers-disease","kind":"indication","name":"Alzheimer's disease","route":"/indications/alzheimers-disease/","asOf":"2026-09-22","days":27},{"id":"parkinsonian-syndromes","kind":"indication","name":"Parkinsonian syndromes","route":"/indications/parkinsonian-syndromes/","asOf":"2026-09-22","days":27},{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","asOf":"2026-09-22","days":27},{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","asOf":"2026-09-22","days":27},{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","asOf":"2026-09-22","days":27},{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","asOf":"2026-09-22","days":27},{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/","asOf":"2026-09-22","days":27},{"id":"tc-99m-hmpao-brain","kind":"drug","name":"Technetium-99m exametazime (brain perfusion)","route":"/drugs/tc-99m-hmpao-brain/","asOf":"2026-09-22","days":27},{"id":"f-18-fdg-brain","kind":"drug","name":"Fludeoxyglucose F-18 (brain metabolism)","route":"/drugs/f-18-fdg-brain/","asOf":"2026-09-22","days":27},{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","asOf":"2026-09-22","days":27},{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","asOf":"2026-09-22","days":27},{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/","asOf":"2026-09-22","days":27},{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","asOf":"2026-09-22","days":27},{"id":"sr-89-chloride","kind":"drug","name":"Strontium-89 chloride","route":"/drugs/sr-89-chloride/","asOf":"2026-09-22","days":27},{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","asOf":"2026-09-22","days":27},{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","asOf":"2026-09-22","days":27},{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","asOf":"2026-09-22","days":27},{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","asOf":"2026-09-22","days":27},{"id":"i-125-seeds","kind":"drug","name":"Iodine-125 brachytherapy seeds","route":"/drugs/i-125-seeds/","asOf":"2026-09-22","days":27},{"id":"ac-225-fpi-2068","kind":"drug","name":"Actinium-225 FPI-2068","route":"/drugs/ac-225-fpi-2068/","asOf":"2026-09-22","days":27},{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","asOf":"2026-09-22","days":27},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","asOf":"2026-09-22","days":27},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","asOf":"2026-09-22","days":27},{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","asOf":"2026-09-22","days":27},{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","asOf":"2026-09-22","days":27},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","asOf":"2026-09-22","days":27},{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","asOf":"2026-09-22","days":27},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","asOf":"2026-09-22","days":27},{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","asOf":"2026-09-22","days":27},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","asOf":"2026-09-22","days":27},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","asOf":"2026-09-22","days":27},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","asOf":"2026-09-22","days":27},{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/","asOf":"2026-09-22","days":27},{"id":"icrp-publications","kind":"collection","name":"ICRP publications and dose coefficient databases","route":"/collections/icrp-publications/","asOf":"2026-09-22","days":27},{"id":"nrc-regulations-part35","kind":"collection","name":"US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)","route":"/collections/nrc-regulations-part35/","asOf":"2026-09-22","days":27},{"id":"iaea-isotope-databases","kind":"collection","name":"IAEA nuclear data and isotope databases","route":"/collections/iaea-isotope-databases/","asOf":"2026-09-22","days":27},{"id":"snmmi-procedure-standards","kind":"collection","name":"SNMMI Procedure Standards","route":"/collections/snmmi-procedure-standards/","asOf":"2026-09-22","days":27},{"id":"eanm-guidelines","kind":"collection","name":"EANM Guidelines","route":"/collections/eanm-guidelines/","asOf":"2026-09-22","days":27},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","asOf":"2026-09-22","days":27},{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","asOf":"2026-09-22","days":27},{"id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","asOf":"2026-09-22","days":27},{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","asOf":"2026-09-22","days":27},{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","asOf":"2026-09-22","days":27},{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","asOf":"2026-09-22","days":27},{"id":"journal-of-nuclear-cardiology","kind":"journal","name":"Journal of Nuclear Cardiology","route":"/journals/journal-of-nuclear-cardiology/","asOf":"2026-09-22","days":27},{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","asOf":"2026-09-22","days":27},{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","asOf":"2026-09-22","days":27},{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","asOf":"2026-09-22","days":27},{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","asOf":"2026-09-22","days":27},{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","asOf":"2026-09-22","days":27},{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","asOf":"2026-09-22","days":27},{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","asOf":"2026-09-22","days":27},{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","asOf":"2026-09-22","days":27},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","asOf":"2026-09-22","days":27},{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/","asOf":"2026-09-22","days":27},{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","asOf":"2026-09-22","days":27},{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","asOf":"2026-09-22","days":27},{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/","asOf":"2026-09-22","days":27},{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","asOf":"2026-09-22","days":27},{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","asOf":"2026-09-22","days":27},{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/","asOf":"2026-09-22","days":27},{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/","asOf":"2026-09-22","days":27},{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/","asOf":"2026-09-22","days":27},{"id":"f-neuro-imaging","kind":"section","name":"Neuro-imaging","route":"/fronts/f-neuro-imaging/","asOf":"2026-09-22","days":27},{"id":"f-cardiac-imaging","kind":"section","name":"Cardiac imaging","route":"/fronts/f-cardiac-imaging/","asOf":"2026-09-22","days":27},{"id":"f-infection-imaging","kind":"section","name":"Infection & inflammation imaging","route":"/fronts/f-infection-imaging/","asOf":"2026-09-22","days":27},{"id":"f-bone-targeted","kind":"section","name":"Bone-targeted radiopharmaceuticals","route":"/fronts/f-bone-targeted/","asOf":"2026-09-22","days":27},{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/","asOf":"2026-09-22","days":27},{"id":"f-regulation-reimbursement","kind":"section","name":"Regulation & reimbursement","route":"/fronts/f-regulation-reimbursement/","asOf":"2026-09-22","days":27},{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/","asOf":"2026-09-22","days":27},{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/","asOf":"2026-09-22","days":27},{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","asOf":"2026-09-22","days":27},{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/","asOf":"2026-09-22","days":27},{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/","asOf":"2026-09-22","days":27},{"id":"idea-neoadjuvant-psma-therapy","kind":"idea","name":"Neoadjuvant PSMA radioligand therapy before prostatectomy","route":"/ideas/idea-neoadjuvant-psma-therapy/","asOf":"2026-09-22","days":27},{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","asOf":"2026-09-22","days":27},{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/","asOf":"2026-09-22","days":27},{"id":"idea-total-body-pet-lower-dose-tracers","kind":"idea","name":"Using total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time","route":"/ideas/idea-total-body-pet-lower-dose-tracers/","asOf":"2026-09-22","days":27},{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/","asOf":"2026-09-22","days":27},{"id":"idea-copper-theranostic-pair-standard","kind":"idea","name":"A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment","route":"/ideas/idea-copper-theranostic-pair-standard/","asOf":"2026-09-22","days":27},{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/","asOf":"2026-09-22","days":27},{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/","asOf":"2026-09-22","days":27},{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/","asOf":"2026-09-22","days":27},{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/","asOf":"2026-09-22","days":27},{"id":"graves-hyperthyroidism","kind":"indication","name":"Graves' disease and hyperthyroidism","route":"/indications/graves-hyperthyroidism/","asOf":"2026-09-22","days":27},{"id":"infection-prosthetic-joint","kind":"indication","name":"Prosthetic joint infection","route":"/indications/infection-prosthetic-joint/","asOf":"2026-09-22","days":27},{"id":"fever-of-unknown-origin","kind":"indication","name":"Fever of unknown origin","route":"/indications/fever-of-unknown-origin/","asOf":"2026-09-22","days":27},{"id":"sentinel-node-mapping","kind":"indication","name":"Sentinel lymph node mapping in breast cancer and melanoma","route":"/indications/sentinel-node-mapping/","asOf":"2026-09-22","days":27},{"id":"renal-obstruction","kind":"indication","name":"Suspected upper urinary tract obstruction","route":"/indications/renal-obstruction/","asOf":"2026-09-22","days":27},{"id":"gastrointestinal-bleeding","kind":"indication","name":"Gastrointestinal bleeding localisation","route":"/indications/gastrointestinal-bleeding/","asOf":"2026-09-22","days":27},{"id":"pulmonary-embolism-vq","kind":"indication","name":"Pulmonary embolism: ventilation/perfusion imaging","route":"/indications/pulmonary-embolism-vq/","asOf":"2026-09-22","days":27},{"id":"bone-pain-palliation","kind":"indication","name":"Bone pain palliation from osteoblastic metastases","route":"/indications/bone-pain-palliation/","asOf":"2026-09-22","days":27},{"id":"epilepsy-localisation","kind":"indication","name":"Presurgical localisation of drug-resistant focal epilepsy","route":"/indications/epilepsy-localisation/","asOf":"2026-09-22","days":27},{"id":"thyroid-nodule-assessment","kind":"indication","name":"Functional assessment of thyroid nodules","route":"/indications/thyroid-nodule-assessment/","asOf":"2026-09-22","days":27},{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/","asOf":"2026-09-22","days":27},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/","asOf":"2026-09-22","days":27},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/","asOf":"2026-09-22","days":27},{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/","asOf":"2026-09-22","days":27},{"id":"i-124","kind":"isotope","name":"Iodine-124","route":"/isotopes/i-124/","asOf":"2026-09-22","days":27},{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/","asOf":"2026-09-22","days":27},{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/","asOf":"2026-09-22","days":27},{"id":"zr-89","kind":"isotope","name":"Zirconium-89","route":"/isotopes/zr-89/","asOf":"2026-09-22","days":27},{"id":"c-11","kind":"isotope","name":"Carbon-11","route":"/isotopes/c-11/","asOf":"2026-09-22","days":27},{"id":"n-13","kind":"isotope","name":"Nitrogen-13","route":"/isotopes/n-13/","asOf":"2026-09-22","days":27},{"id":"o-15","kind":"isotope","name":"Oxygen-15","route":"/isotopes/o-15/","asOf":"2026-09-22","days":27},{"id":"rb-82","kind":"isotope","name":"Rubidium-82","route":"/isotopes/rb-82/","asOf":"2026-09-22","days":27},{"id":"ga-67","kind":"isotope","name":"Gallium-67","route":"/isotopes/ga-67/","asOf":"2026-09-22","days":27},{"id":"tl-201","kind":"isotope","name":"Thallium-201","route":"/isotopes/tl-201/","asOf":"2026-09-22","days":27},{"id":"sc-44","kind":"isotope","name":"Scandium-44","route":"/isotopes/sc-44/","asOf":"2026-09-22","days":27},{"id":"y-86","kind":"isotope","name":"Yttrium-86","route":"/isotopes/y-86/","asOf":"2026-09-22","days":27},{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/","asOf":"2026-09-22","days":27},{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/","asOf":"2026-09-22","days":27},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/","asOf":"2026-09-22","days":27},{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","asOf":"2026-09-22","days":27},{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/","asOf":"2026-09-22","days":27},{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/","asOf":"2026-09-22","days":27},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/","asOf":"2026-09-22","days":27},{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/","asOf":"2026-09-22","days":27},{"id":"bi-213","kind":"isotope","name":"Bismuth-213","route":"/isotopes/bi-213/","asOf":"2026-09-22","days":27},{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/","asOf":"2026-09-22","days":27},{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/","asOf":"2026-09-22","days":27},{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/","asOf":"2026-09-22","days":27},{"id":"sm-153","kind":"isotope","name":"Samarium-153","route":"/isotopes/sm-153/","asOf":"2026-09-22","days":27},{"id":"sr-89","kind":"isotope","name":"Strontium-89","route":"/isotopes/sr-89/","asOf":"2026-09-22","days":27},{"id":"ho-166","kind":"isotope","name":"Holmium-166","route":"/isotopes/ho-166/","asOf":"2026-09-22","days":27},{"id":"re-188","kind":"isotope","name":"Rhenium-188","route":"/isotopes/re-188/","asOf":"2026-09-22","days":27},{"id":"p-32","kind":"isotope","name":"Phosphorus-32","route":"/isotopes/p-32/","asOf":"2026-09-22","days":27},{"id":"th-227","kind":"isotope","name":"Thorium-227","route":"/isotopes/th-227/","asOf":"2026-09-22","days":27},{"id":"ra-224","kind":"isotope","name":"Radium-224","route":"/isotopes/ra-224/","asOf":"2026-09-22","days":27},{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/","asOf":"2026-09-22","days":27},{"id":"pluvicto-plus-olaparib","kind":"pairing","name":"177Lu-PSMA-617 (Pluvicto) with olaparib","route":"/pairings/pluvicto-plus-olaparib/","asOf":"2026-09-22","days":27},{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/","asOf":"2026-09-22","days":27},{"id":"radium223-abiraterone-caution","kind":"pairing","name":"Radium-223 with abiraterone: a caution, not a combination","route":"/pairings/radium223-abiraterone-caution/","asOf":"2026-09-22","days":27},{"id":"fdg-pet-response-adapted-therapy","kind":"pairing","name":"FDG PET then response-adapted chemotherapy","route":"/pairings/fdg-pet-response-adapted-therapy/","asOf":"2026-09-22","days":27},{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","asOf":"2026-09-22","days":27},{"id":"tare-vs-sorafenib-caution","kind":"pairing","name":"Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma","route":"/pairings/tare-vs-sorafenib-caution/","asOf":"2026-09-22","days":27},{"id":"rituximab-then-ibritumomab-tiuxetan","kind":"pairing","name":"Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)","route":"/pairings/rituximab-then-ibritumomab-tiuxetan/","asOf":"2026-09-22","days":27},{"id":"beta-psma-then-alpha-psma-rescue","kind":"pairing","name":"177Lu-PSMA-617 then 225Ac-PSMA rescue therapy","route":"/pairings/beta-psma-then-alpha-psma-rescue/","asOf":"2026-09-22","days":27},{"id":"docetaxel-then-lu177-psma","kind":"pairing","name":"Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617","route":"/pairings/docetaxel-then-lu177-psma/","asOf":"2026-09-22","days":27},{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/","asOf":"2026-09-22","days":27},{"id":"paper-therap-lancet-2021","kind":"paper","name":"TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-therap-lancet-2021/","asOf":"2026-09-22","days":27},{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC","route":"/key-papers/paper-psmafore-lancet-2024/","asOf":"2026-09-22","days":27},{"id":"paper-zircon-lancet-oncol-2024","kind":"paper","name":"ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma","route":"/key-papers/paper-zircon-lancet-oncol-2024/","asOf":"2026-09-22","days":27},{"id":"paper-kratochwil-ac225-psma-jnm-2016","kind":"paper","name":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","route":"/key-papers/paper-kratochwil-ac225-psma-jnm-2016/","asOf":"2026-09-22","days":27},{"id":"paper-strosberg-netter1-qol-jco-2018","kind":"paper","name":"Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate","route":"/key-papers/paper-strosberg-netter1-qol-jco-2018/","asOf":"2026-09-22","days":27},{"id":"paper-hofman-lupsma-lancet-oncol-2018","kind":"paper","name":"LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-hofman-lupsma-lancet-oncol-2018/","asOf":"2026-09-22","days":27},{"id":"paper-sgouros-tat-review-nat-rev-2020","kind":"paper","name":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","route":"/key-papers/paper-sgouros-tat-review-nat-rev-2020/","asOf":"2026-09-22","days":27},{"id":"paper-herrmann-radiotheranostics-lancet-oncol-2020","kind":"paper","name":"Radiotheranostics: a roadmap for future development","route":"/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/","asOf":"2026-09-22","days":27},{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/","asOf":"2026-09-22","days":27},{"id":"paper-jadvar-snmmi-psma-auc-jnm-2022","kind":"paper","name":"Appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging","route":"/key-papers/paper-jadvar-snmmi-psma-auc-jnm-2022/","asOf":"2026-09-22","days":27},{"id":"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022","kind":"paper","name":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","route":"/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/","asOf":"2026-09-22","days":27},{"id":"paper-tagawa-ac225-j591-jco-2024","kind":"paper","name":"Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC","route":"/key-papers/paper-tagawa-ac225-j591-jco-2024/","asOf":"2026-09-22","days":27},{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","asOf":"2026-09-22","days":27},{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","asOf":"2026-09-22","days":27},{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/","asOf":"2026-09-22","days":27},{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","asOf":"2026-09-22","days":27},{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","asOf":"2026-09-22","days":27},{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/","asOf":"2026-09-22","days":27},{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","route":"/people/phillip-kuo/","asOf":"2026-09-22","days":27},{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","asOf":"2026-09-22","days":27},{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","asOf":"2026-09-22","days":27},{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","asOf":"2026-09-22","days":27},{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/","asOf":"2026-09-22","days":27},{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/","asOf":"2026-09-22","days":27},{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/","asOf":"2026-09-22","days":27},{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/","asOf":"2026-09-22","days":27},{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","asOf":"2026-09-22","days":27},{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","asOf":"2026-09-22","days":27},{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","asOf":"2026-09-22","days":27},{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/","asOf":"2026-09-22","days":27},{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/","asOf":"2026-09-22","days":27},{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/","asOf":"2026-09-22","days":27},{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/","asOf":"2026-09-22","days":27},{"id":"caix","kind":"target","name":"CAIX (carbonic anhydrase IX)","route":"/targets/caix/","asOf":"2026-09-22","days":27},{"id":"nis-symporter","kind":"target","name":"NIS (sodium-iodide symporter)","route":"/targets/nis-symporter/","asOf":"2026-09-22","days":27},{"id":"norepinephrine-transporter","kind":"target","name":"Norepinephrine transporter (NET)","route":"/targets/norepinephrine-transporter/","asOf":"2026-09-22","days":27},{"id":"amyloid-beta","kind":"target","name":"Amyloid beta plaques","route":"/targets/amyloid-beta/","asOf":"2026-09-22","days":27},{"id":"tau-protein","kind":"target","name":"Tau protein (neurofibrillary tangles)","route":"/targets/tau-protein/","asOf":"2026-09-22","days":27},{"id":"dopamine-transporter","kind":"target","name":"Dopamine transporter (DAT)","route":"/targets/dopamine-transporter/","asOf":"2026-09-22","days":27},{"id":"bone-hydroxyapatite","kind":"target","name":"Bone mineral (hydroxyapatite)","route":"/targets/bone-hydroxyapatite/","asOf":"2026-09-22","days":27},{"id":"glut-hexokinase","kind":"target","name":"GLUT1 / hexokinase (glucose metabolism)","route":"/targets/glut-hexokinase/","asOf":"2026-09-22","days":27},{"id":"integrin-avb3","kind":"target","name":"Integrin αvβ3","route":"/targets/integrin-avb3/","asOf":"2026-09-22","days":27},{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/","asOf":"2026-09-22","days":27},{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/","asOf":"2026-09-22","days":27},{"id":"mesothelin","kind":"target","name":"Mesothelin (MSLN)","route":"/targets/mesothelin/","asOf":"2026-09-22","days":27},{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/","asOf":"2026-09-22","days":27},{"id":"macropa-chelation","kind":"technology","name":"Macropa chelation","route":"/technologies/macropa-chelation/","asOf":"2026-09-22","days":27},{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/","asOf":"2026-09-22","days":27},{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/","asOf":"2026-09-22","days":27},{"id":"albumin-binder-ligands","kind":"technology","name":"Albumin-binder ligands","route":"/technologies/albumin-binder-ligands/","asOf":"2026-09-22","days":27},{"id":"radiohybrid-chemistry","kind":"technology","name":"Radiohybrid (rh) chemistry","route":"/technologies/radiohybrid-chemistry/","asOf":"2026-09-22","days":27},{"id":"mo99-tc99m-generators","kind":"technology","name":"Molybdenum-99/technetium-99m generators","route":"/technologies/mo99-tc99m-generators/","asOf":"2026-09-22","days":27},{"id":"ge68-ga68-generators","kind":"technology","name":"Germanium-68/gallium-68 generators","route":"/technologies/ge68-ga68-generators/","asOf":"2026-09-22","days":27},{"id":"sr82-rb82-generators","kind":"technology","name":"Strontium-82/rubidium-82 generators","route":"/technologies/sr82-rb82-generators/","asOf":"2026-09-22","days":27},{"id":"automated-synthesis-modules","kind":"technology","name":"Automated synthesis modules","route":"/technologies/automated-synthesis-modules/","asOf":"2026-09-22","days":27},{"id":"hot-cells-and-shielding","kind":"technology","name":"Hot cells and radiation shielding","route":"/technologies/hot-cells-and-shielding/","asOf":"2026-09-22","days":27},{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/","asOf":"2026-09-22","days":27},{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/","asOf":"2026-09-22","days":27},{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/","asOf":"2026-09-22","days":27},{"id":"ai-in-nuclear-medicine","kind":"technology","name":"AI in nuclear medicine","route":"/technologies/ai-in-nuclear-medicine/","asOf":"2026-09-22","days":27},{"id":"cold-kit-formulation","kind":"technology","name":"Cold kit formulation","route":"/technologies/cold-kit-formulation/","asOf":"2026-09-22","days":27},{"id":"radiolabelling-quality-control","kind":"technology","name":"Radiolabelling quality control","route":"/technologies/radiolabelling-quality-control/","asOf":"2026-09-22","days":27},{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","asOf":"2026-09-22","days":27},{"id":"krenning-score","kind":"term","name":"Krenning score","route":"/terms/krenning-score/","asOf":"2026-09-22","days":27},{"id":"psma-rads","kind":"term","name":"PSMA-RADS (PSMA reporting and data system)","route":"/terms/psma-rads/","asOf":"2026-09-22","days":27},{"id":"deauville-for-pet","kind":"term","name":"Deauville five-point scale for PET","route":"/terms/deauville-for-pet/","asOf":"2026-09-22","days":27},{"id":"tumour-to-background-ratio","kind":"term","name":"Tumour-to-background ratio (TBR)","route":"/terms/tumour-to-background-ratio/","asOf":"2026-09-22","days":27},{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/","asOf":"2026-09-22","days":27},{"id":"salivary-gland-toxicity","kind":"term","name":"Salivary gland toxicity (xerostomia) from PSMA radioligand therapy","route":"/terms/salivary-gland-toxicity/","asOf":"2026-09-22","days":27},{"id":"renal-protection-amino-acids","kind":"term","name":"Renal protection with amino acid co-infusion","route":"/terms/renal-protection-amino-acids/","asOf":"2026-09-22","days":27},{"id":"myelosuppression-after-rlt","kind":"term","name":"Myelosuppression after radioligand therapy","route":"/terms/myelosuppression-after-rlt/","asOf":"2026-09-22","days":27},{"id":"extravasation-radiopharmaceutical","kind":"term","name":"Radiopharmaceutical extravasation","route":"/terms/extravasation-radiopharmaceutical/","asOf":"2026-09-22","days":27},{"id":"radiation-safety-officer","kind":"term","name":"Radiation Safety Officer (RSO)","route":"/terms/radiation-safety-officer/","asOf":"2026-09-22","days":27},{"id":"authorized-user","kind":"term","name":"Authorized User (AU)","route":"/terms/authorized-user/","asOf":"2026-09-22","days":27},{"id":"alara","kind":"term","name":"ALARA (as low as is reasonably achievable)","route":"/terms/alara/","asOf":"2026-09-22","days":27},{"id":"hot-lab","kind":"term","name":"Hot lab (radiopharmacy dispensing area)","route":"/terms/hot-lab/","asOf":"2026-09-22","days":27},{"id":"dose-calibrator","kind":"term","name":"Dose calibrator","route":"/terms/dose-calibrator/","asOf":"2026-09-22","days":27},{"id":"radiopharmacy-term","kind":"term","name":"Radiopharmacy (practice and discipline)","route":"/terms/radiopharmacy-term/","asOf":"2026-09-22","days":27},{"id":"release-criteria","kind":"term","name":"Product release criteria (radiopharmaceutical quality control)","route":"/terms/release-criteria/","asOf":"2026-09-22","days":27},{"id":"nrc-licensing","kind":"term","name":"NRC medical-use licensing (10 CFR Part 35)","route":"/terms/nrc-licensing/","asOf":"2026-09-22","days":27},{"id":"patient-release-criteria","kind":"term","name":"Patient release criteria after radioactive treatment","route":"/terms/patient-release-criteria/","asOf":"2026-09-22","days":27},{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/","asOf":"2026-09-22","days":27},{"id":"flare-phenomenon","kind":"term","name":"Flare phenomenon","route":"/terms/flare-phenomenon/","asOf":"2026-09-22","days":27},{"id":"specific-activity","kind":"term","name":"Specific activity and molar activity","route":"/terms/specific-activity/","asOf":"2026-09-22","days":27},{"id":"no-carrier-added","kind":"term","name":"No-carrier-added (n.c.a.) and carrier-added production","route":"/terms/no-carrier-added/","asOf":"2026-09-22","days":27},{"id":"chelator-term","kind":"term","name":"Chelator (bifunctional chelating agent)","route":"/terms/chelator-term/","asOf":"2026-09-22","days":27},{"id":"radiochemical-purity","kind":"term","name":"Radiochemical purity (RCP)","route":"/terms/radiochemical-purity/","asOf":"2026-09-22","days":27},{"id":"radionuclidic-purity","kind":"term","name":"Radionuclidic purity","route":"/terms/radionuclidic-purity/","asOf":"2026-09-22","days":27},{"id":"becquerel-curie","kind":"term","name":"Becquerel and curie (units of radioactivity)","route":"/terms/becquerel-curie/","asOf":"2026-09-22","days":27},{"id":"absorbed-dose-term","kind":"term","name":"Absorbed dose and the gray (Gy)","route":"/terms/absorbed-dose-term/","asOf":"2026-09-22","days":27},{"id":"equivalent-dose","kind":"term","name":"Equivalent dose and effective dose (sievert)","route":"/terms/equivalent-dose/","asOf":"2026-09-22","days":27},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","asOf":"2026-09-22","days":27},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","asOf":"2026-09-22","days":27},{"id":"mird-formalism","kind":"term","name":"MIRD formalism","route":"/terms/mird-formalism/","asOf":"2026-09-22","days":27},{"id":"time-activity-curve","kind":"term","name":"Time-activity curve (TAC)","route":"/terms/time-activity-curve/","asOf":"2026-09-22","days":27},{"id":"biological-half-life","kind":"term","name":"Biological half-life","route":"/terms/biological-half-life/","asOf":"2026-09-22","days":27},{"id":"effective-half-life","kind":"term","name":"Effective half-life","route":"/terms/effective-half-life/","asOf":"2026-09-22","days":27},{"id":"radiolysis","kind":"term","name":"Radiolysis (self-radiolysis of radiopharmaceuticals)","route":"/terms/radiolysis/","asOf":"2026-09-22","days":27},{"id":"decay-correction","kind":"term","name":"Decay correction","route":"/terms/decay-correction/","asOf":"2026-09-22","days":27},{"id":"partial-volume-effect","kind":"term","name":"Partial volume effect (PVE)","route":"/terms/partial-volume-effect/","asOf":"2026-09-22","days":27},{"id":"attenuation-correction","kind":"term","name":"Attenuation correction","route":"/terms/attenuation-correction/","asOf":"2026-09-22","days":27},{"id":"time-of-flight-pet","kind":"term","name":"Time-of-flight (TOF) PET","route":"/terms/time-of-flight-pet/","asOf":"2026-09-22","days":27},{"id":"activity-prescription","kind":"term","name":"Activity prescription: fixed versus dosimetry-guided dosing","route":"/terms/activity-prescription/","asOf":"2026-09-22","days":27},{"id":"zircon","kind":"trial","name":"ZIRCON","route":"/trials/zircon/","asOf":"2026-09-22","days":27},{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","asOf":"2026-09-22","days":27},{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","asOf":"2026-09-22","days":27},{"id":"condor","kind":"trial","name":"CONDOR","route":"/trials/condor/","asOf":"2026-09-22","days":27},{"id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","asOf":"2026-09-22","days":27},{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","asOf":"2026-09-22","days":27},{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","asOf":"2026-09-22","days":27},{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","asOf":"2026-09-22","days":27},{"id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/","asOf":"2026-09-22","days":27},{"id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/","asOf":"2026-09-22","days":27},{"id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","asOf":"2026-09-22","days":27},{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","asOf":"2026-09-22","days":27},{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","asOf":"2026-09-23","days":26},{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/","asOf":"2026-09-23","days":26},{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/","asOf":"2026-09-23","days":26},{"id":"nct03054870","kind":"trial","name":"CYC-009: Technegas versus xenon-133 ventilation imaging","route":"/trials/nct03054870/","asOf":"2026-09-23","days":26},{"id":"kr-81m","kind":"isotope","name":"Krypton-81m","route":"/isotopes/kr-81m/","asOf":"2026-09-23","days":26},{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","asOf":"2026-09-23","days":26},{"id":"cyclopharm","kind":"company","name":"Cyclopharm","route":"/companies/cyclopharm/","asOf":"2026-09-23","days":26},{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","asOf":"2026-09-23","days":26},{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","asOf":"2026-09-23","days":26},{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","asOf":"2026-09-23","days":26},{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","asOf":"2026-09-23","days":26},{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","asOf":"2026-09-23","days":26},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","asOf":"2026-09-23","days":26},{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","asOf":"2026-09-23","days":26},{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","asOf":"2026-09-23","days":26},{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","asOf":"2026-09-23","days":26},{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","asOf":"2026-09-23","days":26},{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","asOf":"2026-09-23","days":26},{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","asOf":"2026-09-23","days":26},{"id":"opp-caix-indeterminate-renal-mass","kind":"opportunity","name":"CAIX imaging of the indeterminate renal mass","route":"/opportunities/opp-caix-indeterminate-renal-mass/","asOf":"2026-09-23","days":26},{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","asOf":"2026-09-23","days":26},{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","asOf":"2026-09-23","days":26},{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","asOf":"2026-09-23","days":26},{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","asOf":"2026-09-23","days":26},{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","asOf":"2026-09-23","days":26},{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","asOf":"2026-09-23","days":26},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","asOf":"2026-09-23","days":26},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","asOf":"2026-09-23","days":26},{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","asOf":"2026-09-23","days":26},{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","asOf":"2026-09-24","days":25},{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","asOf":"2026-09-24","days":25},{"id":"bradykinin-b1-receptor","kind":"target","name":"Bradykinin B1 receptor (B1R)","route":"/targets/bradykinin-b1-receptor/","asOf":"2026-09-24","days":25},{"id":"dlg4-psd95","kind":"target","name":"DLG4 (PSD-95)","route":"/targets/dlg4-psd95/","asOf":"2026-09-24","days":25},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","asOf":"2026-09-27","days":22},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","asOf":"2026-09-27","days":22},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","asOf":"2026-09-27","days":22},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","asOf":"2026-09-27","days":22},{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","asOf":"2026-09-27","days":22},{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","asOf":"2026-09-27","days":22},{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","asOf":"2026-09-27","days":22},{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","asOf":"2026-09-27","days":22},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","asOf":"2026-10-04","days":15},{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","asOf":"2026-10-04","days":15},{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","asOf":"2026-10-04","days":15},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","asOf":"2026-10-11","days":8},{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","asOf":"2026-10-11","days":8}],"summary":{"soc-cites-dead":1,"status-vs-approvals":10,"duplicate-name":20,"future-year-in-text":77,"outcome-no-source":12,"text-vs-structured":1,"unsourced-numbers":3,"approvals-vs-regional":16,"approved-only-live-trials":5,"name-collision-across-kinds":12,"near-duplicate-name":2,"orphan":40,"text-says-approved":3,"unsourced":6}}